EU Compassionate Use Programmes (CUPs)

@article{Sou2012EUCU,
  title={EU Compassionate Use Programmes (CUPs)},
  author={H{\'e}l{\`e}ne Sou},
  journal={Pharmaceutical Medicine},
  year={2012},
  volume={24},
  pages={223-229}
}
  • Hélène Sou
  • Published 1 August 2010
  • Business, Medicine
  • Pharmaceutical Medicine
For some patients, compassionate use programmes (CUPs) are the only way to access promising medicinal products that are not yet authorized and for which clinical trials are either not available or in which these patients cannot participate. For such patients, the CUP benefits can be very important. Although an EU regulatory framework exists, there is no single, centralized EU-wide procedure for CUPs. Each Member State has its own procedures and CUP approvals are governed by national regulatory… Expand
The Evolving Landscape of Early Access Programmes: Comparisons and Implications for Market Access.
TLDR
Early access to highly needed and innovative drugs is clearly valuable and benefits various healthcare stakeholders: patients, doctors, insurers, and other healthcare stakeholders. Expand
Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
TLDR
It is time to replace the current patchwork of practices with systems for expanded access in which criteria are clearly described, responsibilities are assigned and arrangements are made, so that patients will know what (not) to expect from expanded access. Expand
Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.
TLDR
An original typology of alternative access schemes based on their marketing authorization (regulation) and reimbursement (redistribution) status is put forward and it is concluded that this typology can illuminate salient policy dilemmas raised byAlternative access schemes in national drug reimbursement systems. Expand
Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
TLDR
It is concluded that detailed study of the type, size and evolution over time of alternative access schemes can serve as indicators of health policy objectives neglected by standard reimbursement systems. Expand
Roll out of intraveneous artesunate under named patient programmes in the Netherlands, Belgium and France
TLDR
NPPs should be harmonised throughout Europe in order to ensure equal availability of treatment and therapeutic benefit to all Europeans without compromising patient safety, and provide a unique opportunity to study both the benefits and risks of unregistered products for treating rare diseases. Expand
Global Access Programs: A Collaborative Approach for Effective Implementation and Management
TLDR
The triggers for early access requests are considered and the need for companies to develop a global strategy for GAPs in order to respond appropriately to requests forEarly access is examined, along with the considerations affecting the type and scope of GAP. Expand
Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study.
TLDR
It is identified that while MAPs are widely operational there is lack of clinical monitoring, inequity to access, operational issues and lack of transparency and a need for a standardised and mandated policy to mitigate issues with MAPs. Expand
A REVIEW ON CLINICAL TRIALS: WHY TO INTRODUCE ZERO PHASE
TLDR
It is concluded that Phase “0” in clinical trials can work as a useful parameter to measure drug safety at subtherapeutic level and the fundamental requirements of clinical studies conducted under an exploratory IND are reviewed and some common misconceptions regarding phase 0 trials are addressed. Expand
Compassionate Use Cases Treated with Hemoglobin-Based Oxygen Carriers
TLDR
One of the most elusive goals in the modern medical era has been to design a safe and effective asanquinous oxygen therapeutic (OT) - most of the 17 billion people in the world are still without an alternative to blood. Expand
Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey.
TLDR
Policy initiatives and promising practices that demonstrate successful multi-stakeholder engagement can be replicated or used to inform further advocacy and policy development with the aim to address patient unmet needs. Expand
...
1
2
...